GAAP EPS for the first quarter was $1.57 compared to a loss of $0.99 per share in the prior-year quarter. Revenue rose 6% and non-GAAP EPS rose 15% versus the year-ago quarter.
For the second quarter of 2019, Agilent projected EPS to be in the range of $0.70 to $0.72 and revenue to be in the range of $1.255 billion to $1.270 billion.
For FY19, the company lifted the outlook. EPS is now expected to be in the range of $3.03 to $3.07 versus the prior estimate of $3.00 to $3.05. Revenue is now expected to be in the range of $5.15 billion to $5.19 billion compared to the prior estimate of $5.13 billion to $5.17 billion.
“We are pleased to start the year with a strong performance driving excellent revenue and EPS growth and exceeding our guidance,” said CEO Mike McMullen.
Revenue from Life Sciences and Applied Markets Group grew 2%, aided by demand in the pharma, environmental and forensics markets. Agilent CrossLab Group revenue grew 8% year-over-year with strong revenue performance from services and consumables. 13% revenue growth in Diagnostics and Genomics Group was led by demand in NASD, low double-digit growth in pathology related businesses and NGS workflow portfolio.
Agilent stock had gained about 16% in the last 90 days and year-to-date periods.
Follow our Google News edition to get the latest stock market, earnings, and financial news at your fingertips